Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 10/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.60 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.60 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.58 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.58 |
| ▸ | FABP4 | P15090 | 4/20 | 0.57 |
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobenzarit SCHEMBL9621335 | 1.00 | GRIK1 (0.61) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| Lobenzarit SCHEMBL187951 | 0.98 | GRIK1 (0.63) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| Lobenzarit SCHEMBL30753983 | 0.98 | GRIK1 (0.63) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| Lobenzarit SCHEMBL1479150 | 0.97 | GRIK1 (0.61) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| Lobenzarit SCHEMBL7935 | 0.97 | GRIK1 (0.61) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL6140792 | 0.90 | FABP4 (0.62) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL11603313 | 0.89 | GRIK1 (0.62) | GRIK1AKR1C3AKR1C2MEN1USP2 | |
| SCHEMBL14576292 | 0.89 | GRIK1 (0.73) | GRIK1AKR1C3FTOPBRM1FABP4 | |
| SCHEMBL30611313 | 0.89 | GRIK1 (0.73) | GRIK1AKR1C3FTOPBRM1FABP4 | |
| SCHEMBL16489012 | 0.89 | EGFR (0.66) | GRIK1AKR1C3AKR1B10AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243200-A1 | CRYSTAL FORMS OF A POL1 INHIBITOR | PIMERA INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-12257254-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2025-03-25 | — | — | US | disclosed |
| EP-3219716-B1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | PIMERA INC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-11912706-B2 | Crystal forms of a POL1 inhibitor | Pimera, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11866438-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230192694-A1 | NOVEL CRYSTAL FORMS OF A POL1 INHIBITOR | Pimera, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-11623928-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2023-04-11 | — | — | US | disclosed |
| US-11618752-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20230066999-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | KARUS THERAPEUTICS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | disclosed |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | KARUS THERAPEUTICS LIMITED (GB) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243200-A1 | CRYSTAL FORMS OF A POL1 INHIBITOR | POLA1, POLR1A, CTDSP1 | GRIK1 1558/4885AKR1C3 3675/4885AKR1B10 3375/4885 |
| US-11912706-B2 | Crystal forms of a POL1 inhibitor | POLA1, POLR1A, CTDSP1 | GRIK1 1558/4885AKR1C3 3675/4885AKR1B10 3375/4885 |
| US-11618752-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | GRIK1 3472/4885AKR1C3 2032/4885AKR1B10 2263/4885 |
| US-11866438-B2 | Compositions, uses and methods for making them | BAX, CASP3, CASP7 | GRIK1 2916/4885AKR1C3 1825/4885AKR1B10 2035/4885 |
| US-20230192694-A1 | NOVEL CRYSTAL FORMS OF A POL1 INHIBITOR | POLA1, POLR1A, CTDSP1 | GRIK1 1824/4885AKR1C3 4041/4885AKR1B10 3625/4885 |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | GRIK1 3977/4885AKR1C3 1739/4885AKR1B10 879/4885 |
| US-12257254-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | GRIK1 3977/4885AKR1C3 1739/4885AKR1B10 879/4885 |
| US-11623928-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | GRIK1 3472/4885AKR1C3 2032/4885AKR1B10 2263/4885 |
| US-20230066999-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | MCL1, MYC, XIAP | GRIK1 3977/4885AKR1C3 1739/4885AKR1B10 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.